Nucyrna team has expertise both in oligonucleotide and CNS diseases such as ALS.

Oligonucleotide-Jonathan Watts, PhD

1. Nature Biotech: The chemical evolution of oligonucleotide therapies of clinical utility.

2. Nature Medicine: Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide.

3. Full publication list: Google Scholar.

Oligonucleotide-Damon Wang, PhD

1. Nature Reviews Drug Discovery: RNA therapeutics on the rise.

2. Nucleic Acids Research: G-rich motifs within PS-based ASOs drive activation of FXN expression through indirect effects.

3. Full publication list: Google Scholar.

ALS & CNS diseases-Joseph Klim, PhD

1. Nature Neuroscience: ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair.

2. Neuron: Loss of mouse Stmn2 function causes motor neuropathy.

3. Full publication list: PubMed.

ALS & CNS-Evangelos Kiskinis, PhD

1. Neuron: Nucleocytoplasmic proteomic analysis uncovers eRF1 and nonsense-mediated decay as modifiers of ALS/FTD C9orf72 toxicity.

2. Cell Stem Cell: Pathways Disrupted in Human ALS Motor Neurons Identified through Genetic Correction of Mutant SOD1.

3.Full publication list: Google Scholar.

ALS & CNS-Robert Brown, MD, DPhil

1. Nature: Mutations in Cu/Zn superoxide dismutase gene are associated with familial ALS.

2. New England Journal of Medicine: Amyotrophic Lateral Sclerosis.

3. Full publication list: Google Scholar.